Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Recent advances in the management of mucormycosis: from bench to bedside Spellberg B; Walsh TJ; Kontoyiannis DP; Edwards J Jr; Ibrahim ASClin Infect Dis 2009[Jun]; 48 (12): 1743-51Recent therapeutic advances have the potential to improve outcomes of mucormycosis. Lipid formulations of amphotericin B (LFAB) have evolved as the cornerstone of primary therapy for mucormycosis. Posaconazole may be useful as salvage therapy, but it cannot be recommended as primary therapy for mucormycosis on the basis of available data. Preclinical and limited retrospective clinical data suggest that combination LFAB-echinocandin therapy may improve survival during mucormycosis. A definitive trial is needed to confirm these results. Combination therapy with LFAB and the iron chelator, deferasirox, also improved outcomes in animal models of mucormycosis. In contrast, combination polyene-posaconazole therapy was of no benefit in preclinical studies. Adjunctive therapy with recombinant cytokines, hyperbaric oxygen, and/or granulocyte transfusions can be considered for selected patients. Early initiation of therapy is critical to maximizing outcomes; recent developments in polymerase chain reaction technology are advancing early diagnostic strategies. Prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis.|*Case Management[MESH]|Amphotericin B/therapeutic use[MESH]|Antifungal Agents/therapeutic use[MESH]|Benzoates/therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Deferasirox[MESH]|Drug Therapy, Combination[MESH]|Echinocandins/therapeutic use[MESH]|Humans[MESH]|Immunologic Factors/therapeutic use[MESH]|Mucormycosis/diagnosis/*drug therapy[MESH]|Polyenes/therapeutic use[MESH]|Triazoles/therapeutic use[MESH] |
